Ariela Katz

October 02, 2018

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

December 12, 2017

When given neoadjuvant chemotherapy before getting a radical cystectomy, patients with the basal subtype of muscle-invasive bladder cancer (MIBC) saw significantly improved overall survival (OS) compared to those who had a cystectomy alone, according to a recent study.

November 20, 2017

For patients with advanced disease, median survival was improved.

November 06, 2017

An antibody–drug conjugate is being tested in patients with platinum-resistant ovarian cancer.

September 20, 2017

A clinical trial will test whether partial prostate ablation matches radical prostatectomy in effectiveness — with fewer early side effects.

September 20, 2017

After a drop, the frequency of PSA screening for prostate cancer has stabilized.

September 19, 2017

Study: To prolong survival in early-stage prostate cancer that is low-risk, observe instead of operating.

September 19, 2017

A targeted drug for women with ovarian cancer may also benefit men with prostate cancer who have similar genetic mutations. A phase 3 trial is designed to find out.

August 23, 2017

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma (MM) who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

July 10, 2017

A study pairs an IDO inhibitor with PD-1 checkpoint blockade.